BACKGROUND: The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors. PATIENTS AND METHODS: Patients aged ≥ 18 years with histologically or cytologically diagnosed advanced solid tumors for whom no suitable effective therapy exists were included. Patients in four cohorts received topotecan (0.5 mg/m(2)/day × 3 days or 1.0 mg/m(2)/day × 3 days) intravenously in combination with oral olaparib 50, 100 or 200 mg bid for six cycles. The primary objectives were to determine the safety and tolerability and to establish the MTD of olaparib in combination with topotecan. RESULTS: Twenty-one patients were enrolled and 19 received treatment. Dose-limiting toxicities were neutropenia and thrombocytopenia. The MTD was established as topotecan 1.0 mg/m(2)/day × 3 days plus olaparib 100 mg bid. The most common adverse events (AEs) included fatigue and gastrointestinal events. There was an olaparib and topotecan dose-related increase in neutropenia which was dose limiting. CONCLUSIONS: Further development of olaparib and topotecan in combination was not explored due to dose-limiting hematological AEs and the resulting sub-therapeutic MTD.
BACKGROUND: The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors. PATIENTS AND METHODS: Patients aged ≥ 18 years with histologically or cytologically diagnosed advanced solid tumors for whom no suitable effective therapy exists were included. Patients in four cohorts received topotecan (0.5 mg/m(2)/day × 3 days or 1.0 mg/m(2)/day × 3 days) intravenously in combination with oral olaparib 50, 100 or 200 mg bid for six cycles. The primary objectives were to determine the safety and tolerability and to establish the MTD of olaparib in combination with topotecan. RESULTS: Twenty-one patients were enrolled and 19 received treatment. Dose-limiting toxicities were neutropenia and thrombocytopenia. The MTD was established as topotecan 1.0 mg/m(2)/day × 3 days plus olaparib 100 mg bid. The most common adverse events (AEs) included fatigue and gastrointestinal events. There was an olaparib and topotecan dose-related increase in neutropenia which was dose limiting. CONCLUSIONS: Further development of olaparib and topotecan in combination was not explored due to dose-limiting hematological AEs and the resulting sub-therapeutic MTD.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Erin Schuetz; Lubin Lan; Kazuto Yasuda; Richard Kim; Thomas A Kocarek; John Schuetz; Stephen Strom Journal: Mol Pharmacol Date: 2002-09 Impact factor: 4.436
Authors: J von Pawel; J H Schiller; F A Shepherd; S Z Fields; J P Kleisbauer; N G Chrysson; D J Stewart; P I Clark; M C Palmer; A Depierre; J Carmichael; J B Krebs; G Ross; S R Lane; R Gralla Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Bastiaan Evers; Rinske Drost; Eva Schut; Michiel de Bruin; Eline van der Burg; Patrick W B Derksen; Henne Holstege; Xiaoling Liu; Ellen van Drunen; H Berna Beverloo; Graeme C M Smith; Niall M B Martin; Alan Lau; Mark J O'Connor; Jos Jonkers Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245
Authors: Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth Journal: Nature Date: 2008-02-10 Impact factor: 49.962
Authors: Jiuping Ji; Yiping Zhang; Christophe E Redon; William C Reinhold; Alice P Chen; Laura K Fogli; Susan L Holbeck; Ralph E Parchment; Melinda Hollingshead; Joseph E Tomaszewski; Quentin Dudon; Yves Pommier; James H Doroshow; William M Bonner Journal: PLoS One Date: 2017-02-03 Impact factor: 3.240
Authors: Elizabeth Stewart; Ross Goshorn; Cori Bradley; Lyra M Griffiths; Claudia Benavente; Nathaniel R Twarog; Gregory M Miller; William Caufield; Burgess B Freeman; Armita Bahrami; Alberto Pappo; Jianrong Wu; Amos Loh; Åsa Karlström; Chris Calabrese; Brittney Gordon; Lyudmila Tsurkan; M Jason Hatfield; Philip M Potter; Scott E Snyder; Suresh Thiagarajan; Abbas Shirinifard; Andras Sablauer; Anang A Shelat; Michael A Dyer Journal: Cell Rep Date: 2014-10-23 Impact factor: 9.423
Authors: Cody J Peer; Jung-Min Lee; Jeffrey Roth; Louis Rodgers; Jeffers Nguyen; Christina M Annunziata; Lori Minasian; Elise C Kohn; William D Figg Journal: Cancer Chemother Pharmacol Date: 2017-06-02 Impact factor: 3.333
Authors: Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby Journal: Cancer Prev Res (Phila) Date: 2014-05-09
Authors: Sabine Mueller; Samhita Bhargava; Annette M Molinaro; Xiaodong Yang; Ilan Kolkowitz; Aleksandra Olow; Noor Wehmeijer; Sharon Orbach; Justin Chen; Katherine K Matthay; Daphne A Haas-Kogan Journal: Anticancer Res Date: 2013-03 Impact factor: 2.480